Retatrutide
15mg
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. It is the first triagonist to demonstrate substantial efficacy in phase 2 clinical trials, producing mean body weight reductions of up to 24.2% at 48 weeks in participants with obesity. The addition of glucagon receptor agonism differentiates retatrutide from dual agonists by promoting hepatic lipid oxidation, increasing energy expenditure, and enhancing thermogenesis.
Pricing
Mechanism of Action
Retatrutide activates three distinct class B GPCRs: GLP-1R (appetite suppression, insulin secretion), GIPR (adipose tissue remodeling, lipid metabolism), and GCGR (hepatic glycogenolysis, lipid oxidation, energy expenditure via thermogenesis). Glucagon receptor engagement induces hepatic fatty acid oxidation and amino acid catabolism, contributing to fat mass reduction beyond what is achieved by incretin signaling alone. Preclinical data suggest glucagon receptor agonism also increases resting metabolic rate.
Properties
Molecular Formula
C₂₃₅H₃₅₂N₅₄O₆₈S
Molecular Weight
5260 Da (approx.)
Half-Life
~6 days
Storage
Store lyophilized at -20°C. Reconstituted at 2-8°C, use within 30 days.
Research Applications
References & Citations
(3)Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, Kaplan LM, Frías JP, et al.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-comparator-controlled, parallel-group, phase 2 trial
Rosenstock J, Frias JP, Jastreboff AM, et al.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss
Coskun T, Urva S, Roell WC, et al.
Related Products
Research Use Only
This product is intended strictly for in-vitro research, educational, and laboratory use. Not for human consumption. The information provided is based on published research and does not constitute medical advice.